Anti Helicobacter Pylori Formula Shows Initial Results
Helicobacter pylori (Hp) is closely related to the occurrence and development of gastric cancer, peptic ulcer, Hp-related dyspepsia and other diseases. Studies have found that Hp can cause gastric microbial disorders, change the microbial diversity and community structure in the stomach, and cause precancerous lesions. The public health community has made great efforts to eradicate Hp for a long time, but the current Hp infection rate in the entire population is still over 50%. In recent years, probiotics have attracted attention due to their relative safety, and microecological therapy has brought new ideas for the treatment of Hp.
Probiotics are beneficial to the health of the host, and can help inhibit intestinal pathogens, reduce lactose intolerance, and improve constipation. At present, studies have confirmed that supplementing probiotics in the H. pylori eradication program can increase the eradication rate and reduce the occurrence of adverse reactions, but the specific changes in the intestinal flora before and after eradication have not been evaluated. For this reason, Bumjo and others from Seoul National University School of Medicine in South Korea conducted a randomized controlled trial. It has been proved that supplementing with probiotics can reduce the intestinal flora translocation and the growth of drug-resistant bacteria during the eradication process and other antibiotic-related adverse reactions, thereby increasing the eradication rate.
Creative Enzymes provides high-quality anti-H. pylori formula for academic and industrial use. Probiotics represent a low-cost, large-scale alternative solution to prevent or reduce Helicobacter pylori colonization. Based on in vitro studies of host intestinal epithelial or immune cell responses to probiotic strains, several mechanisms have been hypothesized. Probiotics can inhibit Helicobacter pylori through immune or non-immune mechanisms.
1. Introduction to probiotics
Probiotics are currently defined as 'live microorganisms that, when administered in sufficient quantities, can provide the host with health benefits.' Probiotics are the most widely used of microecological preparations (including probiotics, prebiotics, and synbiotics). According to the source of the strain and its mechanism of action, it can be divided into original bacterial preparations, symbiotic preparations, and fungal preparations. Strains of native bacteria preparations are strains derived from the intestinal flora of the human body and can be directly supplemented after taking it, such as Bifidobacterium, Clostridium butyricum, Lactobacillus, and Streptococcus faecalis. The strains of symbiotic bacteria preparations are derived from the human intestinal tract, which can promote the growth and reproduction of native bacteria, or directly play a role, such as Bacillus subtilis and Bacillus. Fungal preparations including Saccharomyces boulardii can also play a regulatory role through a specific mechanism of action.
2. The auxiliary effect of probiotics on HP eradication
The gastrointestinal microecosystem is huge and complex, with many influencing factors. Research on gastrointestinal microecology and HP infection and changes before and after eradication still involve factors such as race, living environment, eradication drugs, treatment course, and administration methods. There is a lack of homogeneity among the studies, and it is difficult to draw consistent conclusions at present.
However, based on the consideration of the interaction between HP and the gastrointestinal microbiota, many researchers have been trying to improve HP eradication programs to reduce the side effects of eradication treatment and improve eradication efficacy. The role of probiotics in HP eradication treatment has attracted much attention. A number of meta-analyses based on randomized controlled trials have shown that probiotics can reduce adverse reactions in HP eradication treatment as adjuncts to conventional HP eradication treatment. However, there are certain differences in whether the eradication rate can be increased.
Probiotics may promote the eradication of HP by increasing the number and activity of other beneficial bacteria in the digestive tract, inhibiting the colonization and growth of HP in the epithelium of the gastric mucosa, reducing inflammation and immune response after HP infection. However, different probiotic strains, different dosages, and different treatment courses may have an impact on the results of the study. Combining these randomized controlled trials and studies may cause misjudgment of the results. Therefore, Dr. Masstricht pointed out that probiotics can increase the HP eradication rate. It is more likely that it reduces the side effects of eradication therapy and indirectly improves compliance, rather than directly combating HP. In the future, more rigorously designed clinical studies are needed to confirm the role of probiotics in HP eradication treatment.
Currently commonly used probiotics in clinical practice include lactic acid bacteria and bifidobacteria. The selection of probiotics, the selection of single strains or mixed strains, and the clear timing, dosage, and treatment of probiotics are of great significance to guide the future eradication of Hp. The combination of probiotics has injected fresh blood into the conventional eradication of H. pylori and shows a promising future. The continued in-depth basic research and larger-scale clinical trials are still the way forward and the direction of efforts.